Predictive value of neuromarkers supported by a set of clinical criteria in patients with mild traumatic brain injury: S100B protein and neuron-specific enolase on trial
Clinical article
Search for other papers by Harald Wolf in
Current site
Google Scholar
PubMed
Search for other papers by Sophie Frantal in
Current site
Google Scholar
PubMed
Search for other papers by Gholam S. Pajenda in
Current site
Google Scholar
PubMed
Search for other papers by Olivia Salameh in
Current site
Google Scholar
PubMed
Search for other papers by Harald Widhalm in
Current site
Google Scholar
PubMed
Search for other papers by Stefan Hajdu in
Current site
Google Scholar
PubMed
Search for other papers by Kambiz Sarahrudi in
Current site
Google Scholar
PubMed
Object
The role of the neuromarkers S100B protein and neuron-specific enolase (NSE) in minor head injury is well established. Moreover, there are sensitive decision rules available in the literature to identify clinically important brain lesions. However, it is not clear if using the biomarkers has an influence on the predictability of the decision rule. The purpose of this study was to determine if a set of preclinical and clinical parameters combined with 2 neuromarker levels could serve as reliable guidance for accurate diagnosis.
Methods
Prospective evaluation of a cohort of head trauma patients with Glasgow Coma Scale scores of 13–15 was performed at an academic, Level I trauma center. Blood samples and cranial CT studies were obtained for all patients within 3 hours after injury. The hypothesis of the study was whether the combination of an increase of S100B and NSE levels in serum and other defined risk factors are associated with a pathological finding on CT. A forward stepwise logistic regression model was used.
Results
The study included 107 head trauma patients with a mean age of 59 ± 23 years. Twenty-five patients (23.4%) had traumatic lesions on CT. Eight patients underwent craniotomy. The analysis provided a model with good overall accuracy for discriminating cases with clinically important brain injury, including the 6 variables of S100B, NSE, nausea, amnesia, vomiting, and loss of consciousness. The area under the curve (AUC) was 0.88 (0.83–0.93). The receiver operating characteristic curve plots detecting clinically important brain injury for the single variables of S100B and NSE showed an AUC of 0.63 and 0.64, respectively.
Conclusions
The integration of the neuromarker panel as part of a diagnostic rule including the high-risk factors of nausea, vomiting, amnesia, and loss of consciousness is safe and reliable in determining a diagnosis, pending the availability of more brain-specific neuromarkers. Clinical trial registration no.: NCT00622778 (ClinicalTrials.gov).
Abbreviations used in this paper:
AUC = area under the curve; GCS = Glasgow Coma Scale; ICH = intracerebral hemorrhage; NSE = neuron-specific enolase; ROC = receiver operating characteristic; TBI = traumatic brain injury.
© Copyright 1944-2023 American Association of Neurological Surgeons